MALDI imaging mass spectrometry in ovarian cancer for tracking, identifying, and validating biomarkers.

Background: Among biomarkers, cancer-antigen 125 (CA-125) is the most studied. We propose an analytical tool to track ovarian carcinoma biomarkers, that is, the MALDI mass spectrometry imaging.

Material/methods: Ovarian carcinomas and benign ovaries were directly analyzed by MALDI-TOF-MS.